Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF-Endoret Mesotherapy for Androgenetic Alopecia
2013-002740-85Phase 4Terminated
- Sponsor
- BTI Biotechnology Institute
- Start
- Nov 2013
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in androgenetic alopecia (AGA) comparing PRGF-Endoret mesotherapy with Placebo mesotherapy (2 arms). Primary endpoint: Hair density. Started Nov 2013; status: terminated.
02
Drugs
PRGF-Endoret
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on 2013-002740-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002740-85.